Subjects: Antibodies, Monoclonal -- therapeutic use and Cost-Benefit Analysis - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Antibodies, Monoclonal -- therapeutic use ✖ Subjects Cost-Benefit Analysis ✖

1. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017
Subject(s):: Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic -- drug therapy
Interleukin-4 Receptor alpha Subunit -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors -- therapeutic use
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Cyclosporine -- therapeutic use
Phosphodiesterase 4 Inhibitors -- adverse effects
Phototherapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

2. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
Subject(s):: Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States

3. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018
Subject(s):: Antibodies, Monoclonal -- therapeutic use
Asthma -- drug therapy
Inflammation -- drug therapy
Antibodies, Monoclonal -- adverse effects
Antibodies, Monoclonal -- economics
Biological Therapy
Cost-Benefit Analysis
Hypersensitivity -- drug therapy
Inflammation -- complications
Treatment Outcome
Humans
United States